PathoQuest, a French spin-out of the Institut Pasteur Paris, has appointed Audrey Brussel, Ph.D. to the newly created position of Viral Safety Leader.
The company, which offers quality control testing solutions for biologics using advanced sequencing technologies and proprietary databases, is expanding its NGS-based testing solutions which are intended to complement or replace traditional viral safety tests. Her responsibilities will include raising global awareness and accelerating the adoption of NGS as a more effective approach for viral safety testing.
With more than 20 years of experience in the pharmaceutical industry, Brussel was Project Leader for the Corporate Biological Safety Unit of LFB. Prior to this, she worked at Sanofi on best practice policies and implementation related to viral safety during drug development and manufacture.
Audrey has also been an author / reviewer for sections of regulatory dossiers focusing on viral safety tests. While at both Sanofi and LFB, she was a company representative to the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) and was also a member of CAACB’s Steering Committee when she was at LFB. Before this, she was a viral clearance study director at Texcell, a French CRO specialized in viral safety.
Brussel received her Ph.D. in Virology and Genetics from the Paris VI University and was a virology post-doctoral fellow at Institut Pasteur.